Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Amgen inc. crawled date : 2021 - 04 - 08 save search
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
BGNE | $131.96 0.08% 0.06% 110K
|
Health Technology
|
| O: 1.06%
H: 0.92%
C: -3.19%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -0.89%
brukinsa
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
Published: 2021-04-08 (Crawled : 12:00) - biospace.com/
BGNE | $131.96 0.08% 0.06% 110K
|
Health Technology
|
| O: 1.06%
H: 0.92%
C: -3.19%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -0.89%
covid phase 2 trial brukinsa
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.